LAUSR

High-grade endometrial cancers (ECs) are an aggressive subset of ECs accounting for 70-80% of EC-related deaths. Currently, staging surgery together with chemotherapy or radiotherapy is the main treatment strategy for these cancers. The widespread use of next-generation sequencing has led to a refined understanding of the genomics of EC with important information in term of prognosis as well as the possibility for precision therapies. However, advances in the genomics assessment of high-grade tumours have been slower due to their lower incidence compared to lowgrade EC. In this article, we will briefly the current state of knowledge of the genomics of G3 endometrioid EC, serous uterine cancer, clear cell carcinoma and uterine carcinosarcoma and discussed its implications for diagnosis and targeted therapy.